John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...

Trinity Biotech (TRIB) has obtained an additional $4M in debt financing from its primary lender, Perceptive Advisors. The additional liquidity ...

We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,” said John Gillard, CEO of Trinity Biotech. “The two largest CGM ...

(RTTNews) - Trinity Biotech plc (TRIB), a biotechnology company ... for its next-generation continuous glucose monitoring or CGM system. The findings show approximately 35 percent improvement ...

Revolutionizing CGM Accessibility and Performance Trinity Biotech’s redesigned ergonomic modular CGM system is designed with affordability, accuracy, and sustainability in mind. The device’s ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

(MENAFN- GlobeNewsWire - Nasdaq) Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Feb. 06, 2025 (GLOBE ...